Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance

Abstract

Immunotherapy has emerged as a major therapeutic strategy for cancer; however, immunotherapy resistance remains a significant challenge. Hypoxia, a key hallmark of the tumor microenvironment resulting from the imbalance between the high oxygen demand of rapidly proliferating cancer cells and the limited supply from abnormal blood vessels, plays a central role in driving immunotherapy resistance. Hypoxia-inducible factor-1α (HIF-1α) and its downstream signaling pathways contribute to this resistance by promoting macrophage polarization toward the protumorigenic M2 phenotype, inducing T cell exhaustion, facilitating immune evasion, enhancing angiogenesis, and activating other resistance mechanisms. The review highlights the mechanisms by which hypoxia regulates resistance to immunotherapy and provides a comprehensive overview of nanotechnology-based strategies designed to counteract hypoxia-induced resistance. Finally, the prospects and challenges of translating nanomedicine-based drug delivery systems into clinical practice for overcoming immunotherapy resistance are outlined.

Keywords

Immunotherapy resistance / HIF-1α / tumor-associated macrophages / T cell exhaustion / immune evasion / vascular normalization / nanomedicine

References

[1] Yang M,Wang R,Li H.Cancer immunotherapy elicited by immunogenic cell death based on smart nanomaterials.Small Methods2023;7:2201381

[2] Petiti J,Menga A.The influence of fatty acid metabolism on T cell function in lung cancer.FEBS J2025;292:3596-615

[3] Feng Y,Wang B.Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy.J Nanobiotechnol2024;22:3005 PMCID:PMC11603847

[4] Sadeghi M,Kheiry H.The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the expression of Heme oxygenase-1 and hypoxia-inducible factor 1-alpha.Cancer Cell Int2024;24:3393 PMCID:PMC11197338

[5] Song CW,Kim M.Role of HIF-1α in the responses of tumors to radiotherapy and chemotherapy.Cancer Res Treat2025;57:1-10 PMCID:PMC11729307

[6] Qi H,Ma Y,Liu K.Mechanisms of HIF1A-mediated immune evasion in gastric cancer and the impact on therapy resistance.Cell Biol Toxicol2024;40:9917 PMCID:PMC11464584

[7] Xun Z,Shen M.Identification of hypoxia-ALCAM^high macrophage- exhausted T cell axis in tumor microenvironment remodeling for immunotherapy resistance.Adv Sci2024;11:e2309885 PMCID:PMC11434037

[8] Lu Y,Guan Q.The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma.J Hepatol2023;79:1172-84

[9] Shi S,Liu C,Ke J.Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment.Front Immunol2025;16:1549276 PMCID:PMC11839635

[10] Rodríguez F,De la Fuente N.Nano-based approved pharmaceuticals for cancer treatment: present and future challenges.Biomolecules2022;12:784 PMCID:PMC9221343

[11] Meng X,Zhao H,Wang Z.Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review.J Nanobiotechnol2024;22:2859 PMCID:PMC11438196

[12] Zhang J,Guo Y.Nanoparticle-mediated cuproptosis and photodynamic synergistic strategy: a novel horizon for cancer therapy.Cancer Med2025;14:e70599 PMCID:PMC11770888

[13] Suvac A,Bristow RG.Tumour hypoxia in driving genomic instability and tumour evolution.Nat Rev Cancer2025;25:167-88

[14] Cheng X,Ge X.Tumor-microenvironment- responsive size-shrinkable drug-delivery nanosystems for deepened penetration into tumors.Front Mol Biosci2020;7:576420 PMCID:PMC7729065

[15] Bhattarai D,Lee K.Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): a “structure–activity relationship” perspective.Med Res Rev2018;38:1404-42

[16] Akanji MA,Adeyemi OS.Hypoxia-inducible factors as an alternative source of treatment strategy for cancer.Oxid Med Cell Longev2019;2019:8547846 PMCID:PMC6710762

[17] Yan Y,Yao H.Nanodelivery systems delivering hypoxia-inducible factor-1 alpha short interfering RNA and antisense oligonucleotide for cancer treatment.Front Nanotechnol2022;4:932976

[18] Hatanaka M,Sakaue M.Hypoxia-inducible factor-3 alpha functions as an accelerator of 3T3-L1 adipose differentiation.Biol Pharm Bull2009;32:1166-72

[19] Mandl M,Depping R.A HIF-1α-driven feed-forward loop augments HIF signalling in Hep3B cells by upregulation of ARNT.Cell Death Dis2016;7:e2284 PMCID:PMC5108338

[20] Ju C,Eltzschig HK.Hypoxia-inducible factors as molecular targets for liver diseases.J Mol Med2016;94:613-27 PMCID:PMC4879168

[21] Lee JW,Jeong JW,Kim KW.Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions.Exp Mol Med2004;36:1-12

[22] Bharadwaj LA,Xavier IJ.l-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 α) in H9c2 cardiomyoblasts.Pharmacol Res2002;45:175-81

[23] Appelhoff RJ,Raval RR.Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.J Biol Chem2004;279:38458-65

[24] Berra E.HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.EMBO J2003;22:4082-90 PMCID:PMC175782

[25] Chua YL,Dassa EP.Stabilization of hypoxia-inducible factor-1α protein in hypoxia occurs independently of mitochondrial reactive oxygen species production.J Biol Chem2010;285:31277-84 PMCID:PMC2951202

[26] Pereira T,Poellinger L.Degradation of the hypoxia-inducible factor 1α, where does it happen?.Cell Cycle2006;5:2720-2

[27] Peng X,Xu R,Mei J.The interplay between HIF-1α and noncoding RNAs in cancer.J Exp Clin Cancer Res2020;39:1535 PMCID:PMC6998277

[28] Kanno H,Yoshizumi T.Role of SOCS and VHL proteins in neuronal differentiation and development.IJMS2023;24:3880 PMCID:PMC9960776

[29] Choudhry H.Advances in hypoxia-inducible factor biology.Cell Metab2018;27:281-98

[30] Smolarz B,Samulak D.Hypoxia-induced factor-1α and its role in endometrial cancer.Anticancer Res2024;44:3697-712

[31] Seymour L,Johnson KR.Roles of post-translational modifications of transcription factors involved in breast cancer hypoxia.Molecules2025;30:645 PMCID:PMC11820228

[32] Zhao Z,Li Y,Zou J.Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients.Clin Transl Oncol2020;22:1892-906

[33] Zhang C,Yang G.Design strategies for enhancing antitumor efficacy through tumor microenvironment exploitation using albumin-based nanosystems: a review.Int J Biol Macromol2024;258:129070

[34] Yang M,Gu P.The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment.Bioact Mater2021;6:1973-87 PMCID:PMC7773537

[35] Liu J,Chen L,Zhang Y.Associations between HIFs and tumor immune checkpoints: mechanism and therapy.Discov Onc2024;15:836 PMCID:PMC10761656

[36] Famta P,Vambhurkar G.Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation.Drug Deliv Transl Res2025;15:389-406

[37] Saha P,Weichhart T.Leveraging macrophage metabolism for anticancer therapy: opportunities and pitfalls.Trends Pharmacol Sci2024;45:335-49

[38] Yuan Q,Yang J.The role of macrophages in liver metastasis: mechanisms and therapeutic prospects.Front Immunol2025;16:1542197 PMCID:PMC11872939

[39] Zhang C,Hao L.Integrin-targeted, activatable nanophototherapeutics for immune modulation: enhancing photoimmunotherapy efficacy in prostate cancer through macrophage reprogramming.Aggregate2025;6:e70001

[40] Vitale I,Coussens LM,Galluzzi L.Macrophages and metabolism in the tumor microenvironment.Cell Metabol2019;30:36-50

[41] He Z.Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment.Front Immunol2021;12:741305 PMCID:PMC8481680

[42] Murdoch C,Lewis CE.Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.Blood2004;104:2224-34

[43] Pyonteck SM,Schuhmacher AJ.CSF-1R inhibition alters macrophage polarization and blocks glioma progression.Nat Med2013;19:1264-72 PMCID:PMC3840724

[44] Tripathi C,Kanchan RK.Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin.Oncotarget2014;5:5350-68 PMCID:PMC4170629

[45] Ke X,Song Y.Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells.Oncol Lett2019;18:5871-8 PMCID:PMC6865149

[46] Pillai SR,Marunaka Y,Fais S.Causes, consequences, and therapy of tumors acidosis.Cancer Metastasis Rev2019;38:205-22 PMCID:PMC6625890

[47] Colegio OR,Szabo AL.Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.Nature2014;513:559-63 PMCID:PMC4301845

[48] Zhao Y,Xu T.Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment.Oncotarget2015;6:39196-210 PMCID:PMC4770766

[49] Paolini L,Beauvillain C.Lactic acidosis together with GM-CSF and M-CSF induces human macrophages toward an inflammatory protumor phenotype.Cancer Immunol Res2020;8:383-95

[50] Zhao Y,Wang X.Macrophage transcriptome modification induced by hypoxia and lactate.Exp Ther Med2019;18:4811-9 PMCID:PMC6878900

[51] Zhang L.Lactic acid promotes macrophage polarization through MCT-HIF1α signaling in gastric cancer.Exp Cell Res2020;388:111846

[52] Bohn T,Luther N.Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages.Nat Immunol2018;19:1319-29

[53] Chen P,Xiong H.Gpr132 sensing of lactate mediates tumor–macrophage interplay to promote breast cancer metastasis.Proc Natl Acad Sci U S A2017;114:580-5 PMCID:PMC5255630

[54] Zhang D,Huang H.Metabolic regulation of gene expression by histone lactylation.Nature2019;574:575-80 PMCID:PMC6818755

[55] Wu JY,Hsieh YT.Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor.Mol Cell2020;77:213-27.e5

[56] Cheng S,Tsai Y.CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma.J Control Release2025;379:967-81

[57] Jiang M,Zhang J.Dual inhibition of endoplasmic reticulum stress and oxidation stress manipulates the polarization of macrophages under hypoxia to sensitize immunotherapy.ACS Nano2021;15:14522-34

[58] Fu Y,Zhang Y.Nanoreactors with cascade catalytic activity reprogram the tumor microenvironment for enhanced immunotherapy by synchronously regulating Treg and macrophage cells.ACS Appl Mater Interfaces2024;16:49053-68

[59] Wang Y,Zhang X.In situ production and precise release of bioactive GM-CSF and siRNA by engineered bacteria for macrophage reprogramming in cancer immunotherapy.Biomaterials2025;317:123037

[60] Huang R,Chen S.The role of tumor-associated macrophages in tumor immune evasion.J Cancer Res Clin Oncol2024;150:5777 PMCID:PMC11076352

[61] Medvedeva GF,Nuzhina J,Dukhinova MS.How macrophages become transcriptionally dysregulated: a hidden impact of antitumor therapy.Int J Mol Sci2021;22:2662 PMCID:PMC7961970

[62] Chen Y,Du W,Chang H.Tumor-associated macrophages: an accomplice in solid tumor progression.J Biomed Sci2019;26:78 PMCID:PMC6800990

[63] Li M,Zhu J,Liang S.Targeting tumor-associated macrophages for cancer treatment.Cell Biosci2022;12:823 PMCID:PMC9172100

[64] Xu B,Song X,Jin W.Mapping the tumor microenvironment in TNBC and deep exploration for M1 macrophages-associated prognostic genes.Front Immunol2022;13:923481 PMCID:PMC9279655

[65] Xu Y,Liu L,Wu J.Role of macrophages in tumor progression and therapy (Review).Int J Oncol2022;60:57 PMCID:PMC8997338

[66] Xu Y,Jin K.Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.J Immunother Cancer2022;10:e003416 PMCID:PMC8961180

[67] Xue VW,Córdoba CAG.Transforming growth factor-β: a multifunctional regulator of cancer immunity.Cancers2020;12:3099 PMCID:PMC7690808

[68] Viola A,Sánchez-Rodríguez R,Castegna A.The metabolic signature of macrophage responses.Front Immunol2019;10:1462 PMCID:PMC6618143

[69] Xiao L,Peng H.Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy.Front Immunol2023;14:1157291 PMCID:PMC10325569

[70] Bied M,Ginhoux F.Roles of macrophages in tumor development: a spatiotemporal perspective.Cell Mol Immunol2023;20:983-92 PMCID:PMC10468537

[71] Wu Q,Yin S.Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer.Hepatology2019;70:198-214 PMCID:PMC6618281

[72] Lubitz GS.Not just neighbours: positive feedback between tumour-associated macrophages and exhausted T cells.Nat Rev Immunol2022;22:3

[73] Kersten K,Combes AJ.Spatiotemporal co-dependency between macrophages and exhausted CD8⁺ T cells in cancer.Cancer Cell2022;40:624-38.e9 PMCID:PMC9197962

[74] Nixon BG,Ji L.Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer.Immunity2022;55:2044-58.e5 PMCID:PMC9649891

[75] Nagaraj S,Pisarev V.Altered recognition of antigen is a mechanism of CD8⁺ T cell tolerance in cancer.Nat Med2007;13:828-35 PMCID:PMC2135607

[76] Li J,Chen X.CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer.OncoImmunology2017;6:e1320011 PMCID:PMC5486179

[77] Hoskin D,Furlong S,Blay J.Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).Int J Oncol2008;32:527-35

[78] Xu S,Yang L.Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.Front Immunol2023;14:1199631 PMCID:PMC10258331

[79] Patsoukis N,Petkova V,Li L.Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.Sci Signal2012;5:ra46 PMCID:PMC5498435

[80] Barkal AA,Markovic M.CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.Nature2019;572:392-6 PMCID:PMC6697206

[81] Zeng S,Kang H,Peng X.Photon-driven dye induction pyroptosis: an emerging anti-tumor immunotherapy paradigm.Angew Chem Int Ed Engl2025;64:e202417899

[82] Wherry EJ.Molecular and cellular insights into T cell exhaustion.Nat Rev Immunol2015;15:486-99 PMCID:PMC4889009

[83] Reina-Campos M,Goldrath AW.CD8⁺ T cell metabolism in infection and cancer.Nat Rev Immunol2021;21:718-38 PMCID:PMC8806153

[84] Wu H,Hochrein SM.Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming.Nat Commun2023;14:6858 PMCID:PMC10611730

[85] Bensaad K,Lewis CA.Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation.Cell Rep2014;9:349-65

[86] Patsoukis N,Chatterjee P.PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.Nat Commun2015;6:6692 PMCID:PMC4389235

[87] Bengsch B,Kurachi M.Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8⁺ T cell exhaustion.Immunity2016;45:358-73 PMCID:PMC4988919

[88] Wouters BG.Hypoxia signalling through mTOR and the unfolded protein response in cancer.Nat Rev Cancer2008;8:851-64

[89] He J,Sun L.Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to Immunotherapy.Cell Commun Signal2024;22:89 PMCID:PMC10832166

[90] Ma S,Lee WC.Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy.Nat Commun2022;13:4118 PMCID:PMC9287350

[91] Mao C,Zhu W.In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy.Nat Commun2024;15:9723 PMCID:PMC11550832

[92] Xue F,Kong C.Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy.Mater Today Bio2024;28:101239 PMCID:PMC11421358

[93] Bigos KJ,Lunj S.Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.Front Oncol2024;14:1331355 PMCID:PMC10861654

[94] Jiang X,Deng X.Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.Mol Cancer2019;18:10 PMCID:PMC6332843

[95] Noman MZ,Janji B.PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.J Exp Med2014;211:781-90 PMCID:PMC4010891

[96] Suresh S,Zhu J.eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.Nat Cancer2020;1:533-45 PMCID:PMC7511089

[97] Ding XC,Zhang XD.The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia.J Hematol Oncol2021;14:92 PMCID:PMC8199387

[98] You L,Wang X.The role of hypoxia-inducible factor 1 in tumor immune evasion.Med Res Rev2021;41:1622-43

[99] Alves CC,Giuliatti S.Structural characterization of the interaction of hypoxia inducible factor-1 with its hypoxia responsive element at the -964G > a variation site of the HLA-G promoter region.Int J Mol Sci2021;22:13046 PMCID:PMC8657931

[100] Wang S,Xia Y.Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.J Transl Med2024;22:130 PMCID:PMC10838004

[101] Labiano S,Bolaños E.Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Oncoimmunology2016;5:e1062967 PMCID:PMC4760326

[102] Hakimi AA,DiNatale RG.A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.Nat Commun2020;11:4168 PMCID:PMC7441387

[103] Wu F,Nai Y,Ma Y.NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis.Cell Death Discov2024;10:241 PMCID:PMC11102480

[104] Lee D,Kim E,Cha JH.PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders.Mol Ther2024;32:4235-55 PMCID:PMC11638837

[105] Shi S,Liu C,Zheng Q.NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance.Front Immunol2025;16:1518664 PMCID:PMC11821961

[106] Wen Q,Wang Z.Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape.Oncol Lett2020;19:2595-601 PMCID:PMC7068669

[107] Mortezaee K.Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: updated.J Cell Mol Med2023;27:311-21 PMCID:PMC9889687

[108] Ho JJD,Cervantes G,Krieger JR.Oxygen-sensitive remodeling of central carbon metabolism by archaic eIF5B.Cell Rep2018;22:17-26 PMCID:PMC5786279

[109] Yu A,Jing L.Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.Cell Death Differ2025;32:776-91 PMCID:PMC11982326

[110] Palazón A,Teijeira A.The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.Cancer Discov2012;2:608-23

[111] Walter Jackson Iii,Salman S.Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy.Sci Adv2024;10:eadq2366 PMCID:PMC11817631

[112] Jiang Z,Hong D.Cancer immunotherapy with “vascular-immune” crosstalk as entry point: associated mechanisms, therapeutic drugs and nano-delivery systems.Int J Nanomedicine2024;19:7383-98 PMCID:PMC11268745

[113] Mattila P,Mattila PS.TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation.Scand J Immunol1992;36:159-65

[114] Xia P,Rye KA.Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway.Proc Natl Acad Sci U S A1998;95:14196-201 PMCID:PMC24350

[115] Liu B,Lyu BC.Expressions of TGF-β2, bFGF and ICAM-1 in lens epithelial cells of complicated cataract with silicone oil tamponade.Int J Ophthalmol2017;10:1034-9 PMCID:PMC5514262

[116] Motz GT,Wang LP.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.Nat Med2014;20:607-15 PMCID:PMC4060245

[117] Norling LV,Cooper D.Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking.FASEB J2008;22:682-90

[118] Buckanovich RJ,Kim S.Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.Nat Med2008;14:28-36

[119] Tan J,Liu T.TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.J Hepatol2023;79:126-40

[120] Engin AB.Indoleamine 2,3-dioxygenase activity-induced acceleration of tumor growth, and protein kinases-related novel therapeutics regimens. In: Engin AB, Engin A, editors. Protein kinase-mediated decisions between life and death. Cham: Springer International Publishing; 2021. pp. 339-56.

[121] Herbert A,Jessup W.Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis.Br J Dermatol2011;164:308-15

[122] Lee WS,Chon HJ.Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.Exp Mol Med2020;52:1475-85 PMCID:PMC8080646

[123] Groth C,Weber R.Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.Br J Cancer2019;120:16-25 PMCID:PMC6325125

[124] Khan O,McDonald S.TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion.Nature2019;571:211-8 PMCID:PMC6713202

[125] Kim CG,Kim Y.VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers.Sci Immunol2019;4:eaay0555

[126] Khan KA.Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.Nat Rev Clin Oncol2018;15:310-24

[127] Goumans MJ,ten Dijke P.TGF-beta signaling in vascular biology and dysfunction.Cell Res2009;19:116-27

[128] Tian M,Schiemann WP.Transforming growth factor-β and the hallmarks of cancer.Cell Signal2011;23:951-62 PMCID:PMC3076078

[129] Falco S. The discovery of placenta growth factor and its biological activity.Exp Mol Med2012;44:1-9 PMCID:PMC3277892

[130] Fukumura D,Amoozgar Z,Jain RK.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol2018;15:325-40 PMCID:PMC5921900

[131] Huang Y,Chan CK,Weissman IL.Improving immune-vascular crosstalk for cancer immunotherapy.Nat Rev Immunol2018;18:195-203 PMCID:PMC5922422

[132] Jiang M,Luo L.A clinically acceptable strategy for sensitizing anti-PD-1 treatment by hypoxia relief.J Control Release2021;335:408-19

[133] Chen A,Kuang J.A versatile nanoplatform for broad-spectrum immunotherapy by reversing the tumor microenvironment.ACS Appl Mater Interfaces2021;13:45335-45

[134] Zhen X,Yuan W.Biointerface-engineered hybrid nanovesicles for targeted reprogramming of tumor microenvironment.Adv Mater2024;36:e2401495

[135] Wu J,Chen L.Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma.Bioact Mater2023;20:259-70 PMCID:PMC9168385

[136] Feng X,Liu Z,Song H.Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy.Int J Pharm2023;639:122970

[137] Fang T,Wang L,Deng Y.Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade.Bioact Mater2024;32:530-42 PMCID:PMC10660011

[138] Zhu L,Guo Z,Zhao Q.Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.J Nanobiotechnology2022;20:521 PMCID:PMC9741809

[139] Zhang X,Sun S.Chiral nanoassembly remodels tumor microenvironment through non-oxygen-dependent depletion lactate for effective photodynamic immunotherapy.Biomaterials2025;319:123203

[140] He M,Xu T.Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief.J Control Release2024;368:233-50

[141] Chang CC,Lee YA.Nanoparticle delivery of MnO₂ and antiangiogenic therapy to overcome hypoxia-driven tumor escape and suppress hepatocellular carcinoma.ACS Appl Mater Interfaces2020;12:44407-19

[142] Bao Y,Li S.Multifunctional tumor-targeting carbon dots for tumor microenvironment activated ferroptosis and immunotherapy in cancer treatment.ACS Appl Mater Interfaces2023;15:56834-45

[143] Sun K,Hu J.Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment.Acta Biomater2022;148:230-43

[144] Gong J,Liu C.Hybrid cell membrane-coated nanoparticles for synergizing sonodynamic therapy and immunotherapy against triple-negative breast cancer.Adv Healthc Mater2025;14:e2404184

[145] Wang Y,Luo Z.Engineering endogenous tumor-associated macrophage-targeted biomimetic nano-RBC to reprogram tumor immunosuppressive microenvironment for enhanced chemo-immunotherapy.Adv Mater2021;33:e2103497

[146] Cao Y,Chen Q.Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.Acta Biomater2023;160:239-51

[147] Liu Y,Shen L.Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.J Control Release2020;323:431-41 PMCID:PMC8601127

[148] Jiang T,Wang T,Chen X.TAM-hijacked immunoreaction rescued by hypoxia-pathway-intervened strategy for enhanced metastatic cancer immunotherapy.Small2024;20:e2305728

[149] Zhao Q,Qin X.Enhanced therapeutic efficacy of combining losartan and chemo-immunotherapy for triple negative breast cancer.Front Immunol2022;13:938439 PMCID:PMC9259940

[150] Zhang D,Chen X.An injectable hydrogel to modulate T cells for cancer immunotherapy.Small2022;18:e2202663

[151] Wang D,Yang WH.Arginine-loaded nano-calcium-phosphate-stabilized lipiodol pickering emulsions potentiates transarterial embolization-immunotherapy.Adv Sci2025;12:e2410484 PMCID:PMC11809372

[152] Chen N,Liu H.Enhancing PD-1 blockade in NSCLC: reprogramming tumor immune microenvironment with albumin-bound statins targeting lipid rafts and mitochondrial respiration.Bioact Mater2025;49:140-53 PMCID:PMC11930202

[153] Zhou Z,Song W.Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy.J Control Release2022;352:793-812

[154] Zhao Z,Liu Y.Tumor microenvironment-activable manganese-boosted catalytic immunotherapy combined with PD-1 checkpoint blockade.ACS Nano2022;16:20400-18

[155] Xiong W,Jiang N.Metformin liposome-mediated PD-L1 downregulation for amplifying the photodynamic immunotherapy efficacy.ACS Appl Mater Interfaces2021;13:8026-41

[156] An J,Liu M,Zhang H.Multi-modal Ca²⁺ nanogenerator via reversing T cell exhaustion for enhanced chemo-immunotherapy.J Control Release2024;372:715-27

[157] Yi L,Zhou Z.A hybrid nanoadjuvant simultaneously depresses PD-L1/TGF-β1 and activates cGAS-STING pathway to overcome radio-immunotherapy resistance.Adv Mater2024;36:e2304328

[158] Wang T,Sun J.Functional co-delivery nanoliposomes based on improving hypoxia for increasing photoimmunotherapy efficacy of cold tumors.Int J Pharm2024;663:124581

[159] Wang S,Hu R.Metabolic intervention liposome boosted lung cancer radio-immunotherapy via hypoxia amelioration and PD-L1 restraint.Adv Sci2023;10:e2207608 PMCID:PMC10288235

[160] Jiang X,Li C.Mitochondrial disruption nanosystem simultaneously depressed programmed death ligand-1 and transforming growth factor-β to overcome photodynamic immunotherapy resistance.ACS Nano2024;18:3331-48

[161] Chen Y,Jana D.Priming of cancer-immunity cycle by alleviating hypoxia-induced ferroptosis resistance and immunosuppression.Biomaterials2025;315:122911

[162] Wu Q,Zhang H.WO_3-x@ferrocene-folic acid composites induce cancer cell death and activate immunity via PTT/CDT.Small2025;21:e2500104

[163] Zhang X,He X.HIF-1 inhibitor-based one-stone-two-birds strategy for enhanced cancer chemodynamic-immunotherapy.J Control Release2023;356:649-62

[164] Wang Z,Dong R.TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer.J Nanobiotechnology2023;21:440 PMCID:PMC10664313

[165] Ji Y,Shi G.Triggered cascade-activation nanoplatform to alleviate hypoxia for effective tumor immunotherapy guided by NIR-II imaging.ACS Nano2024;18:31421-34

[166] Taleb M,Wang Y.Bifunctional therapeutic peptide assembled nanoparticles exerting improved activities of tumor vessel normalization and immune checkpoint inhibition.Adv Healthc Mater2021;10:e2100051

[167] Lan J,Li Z.Biomimetic nanomodulators with synergism of photothermal therapy and vessel normalization for boosting potent anticancer immunity.Adv Mater2024;36:e2408511

[168] Li J,Yao W.iRGD-mediated liposomal nanoplatforms for improving hepatocellular carcinoma targeted combination immunotherapy and monitoring tumor response via IVIM-MRI.J Mater Chem B2024;12:9963-78

[169] Zheng X,Tang D.Near-infrared-II nanoparticles for vascular normalization combined with immune checkpoint blockade via photodynamic immunotherapy inhibit uveal melanoma growth and metastasis.Adv Sci2023;10:e2206932 PMCID:PMC10724444

[170] Zhang D,Zheng X.Normalization of tumor vessels by lenvatinib-based metallo-nanodrugs alleviates hypoxia and enhances calreticulin-mediated immune responses in orthotopic HCC and organoids.Small2023;19:e2207786

[171] Feng X,Wu L.Self-delivery nanodrug to manipulate tumor microenvironment for boosting photodynamic cancer immunotherapy.Biomed Pharmacother2024;178:117220

[172] Zhou Y,Hou Z,Jiang Y.Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation.Nanoscale Horiz2021;6:120-31

[173] Li F,Liu D.Vascular disruptive hydrogel platform for enhanced chemotherapy and anti-angiogenesis through alleviation of immune surveillance.Pharmaceutics2022;14:1809 PMCID:PMC9505154

[174] Zhou Z,Liu Y.Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy.Acta Pharm Sin B2022;12:4204-23 PMCID:PMC9643273

[175] Wang-Bishop L,Ngwa VM.STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.Sci Immunol2023;8:eadd1153 PMCID:PMC10226150